Connect

Collins urges Trump Administration to stand up for patients

May 16, 2019
Press Release

WASHINGTON—Rep. Doug Collins (R-Ga.) released the following statement after the Centers for Medicare & Medicaid Services (CMS) issued the Medicare Advantage and Part D Drug Pricing Final Rule (CMS-4180-F).

“I am disappointed today’s final rule gives pharmacy benefit managers (PBMs) greater dominance at the expense of patients and pharmacies. For nearly seven months, I have urged the Trump Administration to finalize certain provisions within the rule to lower prescription drug costs and increase transparency surrounding Medicare Parts C and D. I encourage the Trump Administration to incorporate provisions to eliminate retroactive pharmacy direct and indirect remuneration (DIR) fees and fulfill their longstanding promise to lower drug prices and stand up for patients at the pharmacy counter.”

In November 2018, the Centers for Medicare and Medicaid Services released a proposed rule to lower prescription drug costs and increase transparency surrounding Medicare Parts C and D. Included in the proposal is the bulk of the Phair Pricing Act, which Rep. Doug Collins (R-Ga.) introduced in May 2018, and again in February 2019, to lower drug costs to Medicare patients at the point of sale. 

Issues: